
Is the risk of cardiovascular disease altered with anti‐inflammatory therapies? Insights from rheumatoid arthritis
Author(s) -
Kraakman Michael J,
Dragoljevic Dragana,
Kammoun Helene L,
Murphy Andrew J
Publication year - 2016
Publication title -
clinical and translational immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.321
H-Index - 34
ISSN - 2050-0068
DOI - 10.1038/cti.2016.31
Subject(s) - dyslipidemia , medicine , rheumatoid arthritis , inflammation , disease , context (archaeology) , inflammatory arthritis , arthritis , immunology , bioinformatics , paleontology , biology
Cardiovascular disease (CVD) remains the leading cause of mortality worldwide. Atherosclerosis is the most common form of CVD, which is complex and multifactorial with an elevated risk observed in people with either metabolic or inflammatory diseases. Accumulating evidence now links obesity with a state of chronic low‐grade inflammation and has renewed our understanding of this condition and its associated comorbidities. An emerging theme linking disease states with atherosclerosis is the increased production of myeloid cells, which can initiate and exacerbate atherogenesis. Although anti‐inflammatory drug treatments exist and have been successfully used to treat inflammatory conditions such as rheumatoid arthritis (RA), a commonly observed side effect is dyslipidemia, inadvertently, a major risk factor for the development of atherosclerosis. The mechanisms leading to dyslipidemia associated with anti‐inflammatory drug use and whether CVD risk is actually increased by this dyslipidemia are of great therapeutic importance and currently remain poorly understood. Here we review recent data providing links between inflammation, hematopoiesis, dyslipidemia and CVD risk in the context of anti‐inflammatory drug use.